← Analyst Upside
AU · rank #16 · 2026-10-23
VIRP
PARIS · EUR · $3.29B (USD)
SignalBuy1.7strength 1.7 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.096 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.05 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $410.75 | +17.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +5.98% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.63 |
| Gross margin TTM | +67.2% |
| 52w high | $387.79 |
| Market cap (USD) | $3.29B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Virbac SA develops, manufactures, and markets specialty companion- and farm-animal health pharmaceuticals, vaccines, and nutritional products.
Rationale
17.4% analyst target upside and strong positive 60/90-day EPS revisions (+€0.84) are supported by 9M 2026 organic revenue growth of 7.9% tracking toward the upper end of full-year guidance.
Material risks
- 1Temporary supply chain bottlenecks and toll-manufacturing regulatory constraints in North America, France, and Belgium disrupting product availability.
- 2Execution risks tied to €125 million in industrial capex and complex manufacturing facility transfers for core products such as Suprelorin.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed